Attendee search 

MaveriX Oncology is exploiting cancer and immune cell metabolism to discover and develop new targeted therapeutics that challenge the limitations of current chemotherapy and immunotherapy. The MaveriX technology approach is a multi-target, multi-asset small-molecule platform with potential first and best-in-class therapeutics designed for monotherapy and combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bring new and improved treatments to patients that suffer from cancer. Our lead program MVX5005 (E037) is well tolerated and exhibits broad, single- agent anti-tumor activity in preclinical mouse models of cancer. The unique mechanism-of-action targets cancer cells directly, induces immunogenic cell death while eradicating immune suppressive cells within the tumor microenvironment. E037 is currently completing IND-enabling studies targeting clinical entry Q3 2021. The company is currently raising capital and seeking strategic partnership opportunities to support clinical development to POC with differentiated platform expansion.

MaveriX Oncology, Inc., is a globally-orientated biotechnology company focused on the discovery and development of novel targeted small-molecule chemo-immunotherapies. The MaveriX technology approach exploits oncogenic and immunogenic targets that are over-expressed to a high frequency in the majority of solid tumors and hematological malignancies. This is a multi-target, multi-asset small-molecule platform technology with potential first and best-in-class therapeutics designed primarily for monotherapy activity in the clinic but with a robust mechanistic rational for combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bringing new and improved treatments to patients suffering from cancer. Our lead program MVX5005 (E037) is well tolerated with broad single agent anti-tumor activity, can overcome key resistance mechanisms in cancer, and challenge the limitations of current chemotherapy and immunotherapy approaches. MVX5005 is currently completing formal IND-enabling studies, targeting clinical entry beginning Q3 2021 (phase 1a dose escalation with disease-specific expansion cohorts for monotherapy plus phase 1b combination chemotherapy and immunotherapy).

An investment group transforming

the world of healthcare one sector at a time.

We consolidate CROs and medical labs.

An investment firm focused on early-stage Biotech and MedTech startups.

An innovative company to partner with emerging biotech companies in drug clinical development and commercialization through United States and China alliance of drug development.

Life Science and Healthcare Venture Capital Investor

Medical Device Company

Tianda Pharmaceutical Limited (455.HK) is a Hong Kong listing company, concentrated in the R&D, manufacturing and distribution of biochemicals, biologics, biosimilars, CHC, dietary supplements and TCM.The company has two pharmaceutical factories, one TCM herbal slice plant, one GSP Company, one CSO company and a R&D center, and several operating
platforms separately located in Sydney, Hong Kong, Shenzhen, Zhuhai and Kunming.Shanghai Pharmaceutical Holding Co Limited, one of the top three largest pharmaceutical companies in China, has invested in Tianda Pharmaceuticals.
The mutual parties share their resources, therefore Tianda could explore and develop its business by utilizing the resources of Shanghai Pharmaceuticals.

A clinical stage bio pharmaceutical company focus on immunotherapy of tumor and autoimmune diseases.

Selfit is a digital therapy startup focusing on the aging population and brain and heart conditions.
The company has developed a therapist robot based on AI and neuroscience with focus on physical and cognitive health.

Arctoris, the world's first fully-automated drug discovery laboratory, provides a revolutionary service - delivering drug discovery data on demand to scientists in biotech, pharma and academia engaged in preclinical research. Thanks to end-to-end automation technologies, Arctoris enables scientists from anywhere in the world to conduct cutting-edge drug discovery research with just their ideas and an internet connection. This is the future of research.

Scientists using the Arctoris platform are able to step away from the laboratory and its time-consuming manual tasks and resume more valuable intellectual activities. Arctoris produces rich, reproducible and structured data, whilst removing the need to set-up and operate expensive laboratories - a compelling proposition for scientists of all industries. Arctoris raises the standard of research, making it faster, more cost-effective, and more reliable.

Get in contact to discuss how Arctoris can augment your research and accelerate your discovery.